We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+13.86%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$421M
AUM Growth
+$85.4M
Cap. Flow
+$55.9M
Cap. Flow %
13.26%
Top 10 Hldgs %
50.23%
Holding
96
New
22
Increased
24
Reduced
22
Closed
7

Top Buys

Rank Stock Value
1
NRIX icon
Nurix Therapeutics
NRIX
+$11.6M
2
RVMD icon
Revolution Medicines
RVMD
+$5.77M
3
PLX icon
Protalix BioTherapeutics
PLX
+$5.61M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.51M
5
ACET icon
Adicet Bio
ACET
+$4.41M

Top Sells

Rank Stock Value
1
FLNA
Filana Therapeutics
FLNA
+$3.07M
2
STIM icon
Neuronetics
STIM
+$2.91M
3
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$2.9M
4
AGTC
Applied Genetic Technologies Corporation
AGTC
+$2.46M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$1.95M

Sector Composition

Rank Sector Weight
1 Healthcare 90.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LMNX
26
DELISTED
Luminex Corp
LMNX
$4.92M 1.17%
154,091
– –
ARAY icon
27
Accuray
ARAY
$33.8M
$4.66M 1.11%
941,800
-32,600
-3% -$168K
HOOK
28
DELISTED
HOOKIPA Pharma
HOOK
$4.62M 1.1%
34,346
+9,346
+37% +$1.13M
MREO
29
Mereo BioPharma
MREO
$48.8M
$4.21M 1%
1,249,648
+581,500
+87% +$2.06M
TBIO
30
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$3.72M 0.88%
225,393
– –
RDHL
31
Redhill Biopharma
RDHL
$3.53M
$3.34M 0.79%
+456
New +$3.83M
MRUS
32
DELISTED
Merus
MRUS
$3.3M 0.78%
+157,841
New +$3.64M
STIM icon
33
Neuronetics
STIM
$157M
$3.14M 0.74%
253,717
-190,000
-43% -$2.91M
ASND icon
34
Ascendis Pharma A/S
ASND
$16.4B
$3M 0.71%
23,237
– –
PRDS
35
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$2.99M 0.71%
+300,000
New +$3.1M
VERO
36
DELISTED
Venus Concept
VERO
$2.89M 0.69%
7,457
-1,634
-18% -$651K
VKTX icon
37
Viking Therapeutics
VKTX
$3.88B
$2.83M 0.67%
447,400
-8,500
-2% -$59.8K
HARP
38
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.65M 0.63%
12,666
+4,154
+49% +$833K
ALEC icon
39
Alector
ALEC
$203M
$2.57M 0.61%
127,500
– –
ETNB
40
DELISTED
89bio
ETNB
$2.5M 0.59%
105,478
– –
NTUS
41
DELISTED
Natus Medical Inc
NTUS
$2.45M 0.58%
95,653
+10,078
+12% +$258K
IFRX icon
42
InflaRx
IFRX
$253M
$2.34M 0.56%
+600,000
New +$3.07M
ASLN
43
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$2.27M 0.54%
+16,938
New +$2.15M
LITS
44
Lite Strategy Inc
LITS
$31.6M
$2.22M 0.53%
32,300
-2,250
-7% -$157K
AGTC
45
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.18M 0.52%
430,111
-473,318
-52% -$2.46M
ACAD icon
46
Acadia Pharmaceuticals
ACAD
$4.9B
$2.14M 0.51%
+83,000
New +$3.65M
PHAS
47
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$2.09M 0.5%
603,042
+282,500
+88% +$1.15M
IRON icon
48
Disc Medicine
IRON
$2.97B
$2.03M 0.48%
+5,000
New +$2.23M
MRSN
49
DELISTED
Mersana Therapeutics
MRSN
$2.01M 0.48%
4,971
+3,000
+152% +$1.46M
COGT icon
50
Cogent Biosciences
COGT
$7.14B
$1.96M 0.47%
+223,554
New +$2.15M
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, DAFNA Capital Management held 96 positions worth $421M, up 25% from $336M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DAFNA Capital Management deployed $55.9M of net new capital in Q1 2021, opening 22 new positions and adding to 24 existing holdings. Its largest new stake was Nurix Therapeutics: 306,320 shares worth $9.52M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier.

On the sell side, the largest reduction was Neuronetics, an estimated $2.91M trimmed.

  • DAFNA Capital Management's largest Q1 2021 buy was Nurix Therapeutics: 306,320 shares worth $9.52M.
  • DAFNA Capital Management added most to Revolution Medicines in Q1 2021, an estimated $5.77M increase.
  • DAFNA Capital Management's biggest Q1 2021 reduction was Neuronetics, cutting an estimated $2.91M.
  • DAFNA Capital Management fully exited Filana Therapeutics in Q1 2021, selling an estimated $3.07M.
  • DAFNA Capital Management's ten largest holdings make up 50% of its $421M portfolio in Q1 2021.
  • DAFNA Capital Management opened 22 new positions and closed 7 in Q1 2021.
  • DAFNA Capital Management's portfolio value rose 25% quarter-over-quarter to $421M.

Based on DAFNA Capital Management's 13F filing for Q1 2021, filed 17 May 2021.